Join our daily newsletter At The Bell to receive exclusive market insights
- Total Brain (TTB) shares have jumped up after the mental health support platform inked a non-exclusive license deal with Janssen Research & Development
- TTB will receive a one-off fee of US$2.2 million (A$3.1 million) under the agreement, in return for handing over its iSPOT-D research data
- The company developed an objective Personalised Medicine Test to determine who is likely to respond to three of the most common antidepressant medications
- The ASX-listed healthcare stock is also a sponsor of the International Study to Predict Optimized Treatment in Depression
- Shares in TTB are up 52.6 per cent at 14.5 cents each
Total Brain (TTB) shares have jumped up after the mental health support platform inked a non-exclusive license deal with Janssen Research & Development.
Janssen, which forms part of the wider Johnson & Johnson business, will pay a one-off fee of US$2.2 million (A$3.1 million) under the agreement.
In return, Total Brain will hand over its International Study to Predict Optimized Treatment in Depression (iSPOT-D) research data.
The license is subject to conventional commercial termination provisions and will come in to effect immediately.
TTB previously developed an objective Personalised Medicine Test to determine who is likely to respond to three of the most common antidepressant medications.
It also sponsors iSPOT-D, a global study that looks for markers that predict specific responses to a range of antidepressants for those with depression.
Finally, the business provides a software as a service (SaaS) mental health monitoring and support app called Total Brain.
Following today’s licensing deal news, shares in TTB have jumped up over 50 per cent during morning trade.
Total Brain was still up 52.6 per cent at 14.5 cents each at 1:12 pm AEDT.
